Acumen Pharmaceuticals, Inc. Q4 FY2025 earnings call

2025 was a year of execution and expansion at Acumen. Made clinical progress for lead program Sobernatug in Phase II altitude AD trial. Expanded pipeline with enhanced brain delivery partnership with JCR Pharmaceuticals. 2026 poised to be transformative year with expectation to read out altitude AD late 2026. EBD program gaining momentum with preclinical data announced last week. Jim discussed details of EBD candidates consisting of cargo and carrier components. Matt provided financials: ended 2025 with $116.9 million in cash and marketable securities, R&D expenses $104.9 million, G&A expenses $18.9 million, net loss $121.3 million, and $35.75 million private placement for EBD program.

Not provided in detail in the transcript

Expect to read out altitude AD late 2026. EBD program targeting filing of an IND for a clinical candidate in mid-2027. Confident in scientific innovation and track record of execution towards phase two altitude AD readout and EBD program advancement.

Forward-looking statements subject to risks and uncertainties that could cause actual results to differ materially from those described. Risks related to clinical trial outcomes, development progress, and potential differences from forward-looking statements.

Q: Related to altitude AD study, how has patient retention been, trend vs initial assumptions, rollover into OLE progress, and relation to safety, tolerability vs other studies.

A: Jim and Eric responded that retention and rollover rates are in line with other major Alzheimer's trials, metrics consistent with trial progressing nicely, and study continues forward with no out-of-line issues observed so far.

Q: Planning to present additional NHP preclinical data for EBD program, what to expect; and how much more EBD can improve on subornatug's selectivity.

A: Jim responded that they've been increasingly presenting EBD program data at major scientific meetings, will continue to tell the story in upcoming meetings, and EBD technology supercharges antibodies to enhance brain distribution with multiple benefits.

Q: Potential of EBD-enhanced molecule's distribution within brain of different A-beta species; and why lower rates of anemia with EBD.

A: Jason responded that soluble oligomers have broad distribution across cortical and subcortical regions, and JCR's technology has reason to think for lower anemia rates due to specific epitopes targeting on transferrin receptor.

Q: Planning for IND targeted mid-2027 for EBD program, trial design; and feedback on Suburban Tech's unmet need address.

A: Jim responded on trial design considerations to take advantage of Subarnatog studies' learnings, and Eric spoke on positioning Subarnatug considering approved drugs and ARIA safety.

Q: OL dosing dose selection, phase three design if altitude AD positive; and variability in NHP exposure, 40X candidate anemia profile.

A: Dev Prasad's questions were addressed with responses on trial design considerations, dose selection reasoning, variability factors in EBD, and discussion on phase three design and anemia profile.